| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
PHARMACOKINETICS |
From Vicuron Pharmaceuticals, King of Prussia, Pennsylvania.
Dalbavancin is a lipoglycopeptide antibiotic in clinical development as a once-weekly treatment for serious infections. A total of 532 patients, consisting of 502 patients with skin and soft tissue infections requiring parenteral therapy and 30 patients with catheter-related bloodstream infections, was available for population pharmacokinetic analysis. The majority of patients (78.4%) received dalbavancin intravenously as a 1000-mg dose on day 1 and a single 500-mg dose on day 8. A 2-compartment model with first-order elimination provided the best fit to the data. The clearance of dalbavancin was influenced by body surface area and creatinine clearance, but together they described less than 25% of the interpatient variability. Body surface area was determined to be a predictor of the central volume of distribution. There was no evidence that the presence of metabolic substrates, inhibitors, or inducers of cytochrome P450 or selected concomitant medications influenced the clearance of dalbavancin.
Key Words: Dalbavancin • population pharmacokinetics • lipoglycopeptide
Address for reprints: Mary Buckwalter, MS, 455 South Gulph Road, King of Prussia, PA 19406; e-mail: mbuckwalter{at}vicuron.com.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Marbury, J. A. Dowell, E. Seltzer, and M. Buckwalter Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment J. Clin. Pharmacol., April 1, 2009; 49(4): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Dowell, B. P. Goldstein, M. Buckwalter, M. Stogniew, and B. Damle Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic J. Clin. Pharmacol., September 1, 2008; 48(9): 1063 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bailey and K. M. Summers Dalbavancin: A new lipoglycopeptide antibiotic Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 599 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Solon, J. A. Dowell, J. Lee, S. P. King, and B. D. Damle Distribution of Radioactivity in Bone and Related Structures following Administration of [14C]Dalbavancin to New Zealand White Rabbits Antimicrob. Agents Chemother., August 1, 2007; 51(8): 3008 - 3010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Andes and W. A. Craig In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1633 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Goldstein, D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm Bactericidal Activity and Resistance Development Profiling of Dalbavancin Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1150 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Jones, H. S. Sader, T. R. Fritsche, P. A. Hogan, and D. J. Sheehan Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program J. Clin. Microbiol., July 1, 2006; 44(7): 2622 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Lin, P. L Carver, and D. D DePestel Dalbavancin: A New Option for the Treatment of Gram-Positive Infections Ann. Pharmacother., March 1, 2006; 40(3): 449 - 460. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
